In addition, we have also excluded (data not shown) the involvement of the SUMO pathway in the surface expression regulation of CS1 (CD2 subset 1), a surface molecule of the SLAM family highly expressed on MM cells that represents a promising target for the treatment of MM46. The gene discussed is SLAMF1; the disease is Miyoshi myopathy.